Capricor Therapeutics (CAPR) Revenue & Revenue Breakdown
Capricor Therapeutics Revenue Highlights
Latest Revenue (Y)
$22.27M
Capricor Therapeutics Revenue by Period
Capricor Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $22.27M | -11.55% |
| 2023-12-31 | $25.18M | 887.79% |
| 2022-12-31 | $2.55M | 940.81% |
| 2021-12-31 | $244.90K | -21.06% |
| 2020-12-31 | $310.25K | -69.13% |
| 2019-12-31 | $1.01M | -39.87% |
| 2018-12-31 | $1.67M | 22.25% |
| 2017-12-31 | $1.37M | -57.14% |
| 2016-12-31 | $3.19M | -15.52% |
| 2015-12-31 | $3.78M | -21.11% |
| 2014-12-31 | $4.79M | 851.19% |
| 2013-12-31 | $503.23K | 157.41% |
| 2012-12-31 | $195.50K | -85.57% |
| 2011-12-31 | $1.35M | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2008-12-31 | - | -100.00% |
| 2007-12-31 | $101.40K | 100.00% |
| 2006-12-31 | - | 100.00% |
| 2005-12-31 | - | 100.00% |
| 2004-12-31 | - | -100.00% |
| 2003-12-31 | $2.18K | -80.98% |
| 2002-12-31 | $11.48K | 100.00% |
| 2001-12-31 | - | 100.00% |
| 2000-12-31 | - | 100.00% |
| 1999-12-31 | - | - |
Capricor Therapeutics generated $22.27M in revenue during NA 2024, up -11.55% compared to the previous quarter, and up 2215.90% compared to the same period a year ago.
Capricor Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2025-06-30 | - | 100.00% |
| 2025-03-31 | - | -100.00% |
| 2024-12-31 | $11.13M | 392.09% |
| 2024-09-30 | $2.26M | -43.04% |
| 2024-06-30 | $3.97M | -19.07% |
| 2024-03-31 | $4.91M | -59.41% |
| 2023-12-31 | $12.09M | 95.41% |
| 2023-09-30 | $6.19M | 57.93% |
| 2023-06-30 | $3.92M | 31.13% |
| 2023-03-31 | $2.99M | 211.18% |
| 2022-12-31 | $959.90K | -39.70% |
| 2022-09-30 | $1.59M | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $204.08K | 400.00% |
| 2021-03-31 | $40.82K | -29.42% |
| 2020-12-31 | $57.83K | 242.94% |
| 2020-09-30 | $16.86K | -66.18% |
| 2020-06-30 | $49.86K | -73.15% |
| 2020-03-31 | $185.69K | -16.39% |
| 2019-12-31 | $222.10K | 56.33% |
| 2019-09-30 | $142.07K | -65.38% |
| 2019-06-30 | $410.35K | 78.02% |
| 2019-03-31 | $230.50K | -64.43% |
| 2018-12-31 | $648.08K | 195.59% |
| 2018-09-30 | $219.25K | -45.73% |
| 2018-06-30 | $403.96K | 0.97% |
| 2018-03-31 | $400.07K | 100.00% |
| 2017-12-31 | - | -100.00% |
| 2017-09-30 | $313.27K | -54.17% |
| 2017-06-30 | $683.59K | -22.39% |
| 2017-03-31 | $880.81K | 28.85% |
| 2016-12-31 | $683.60K | - |
| 2016-09-30 | $683.60K | -39.50% |
| 2016-06-30 | $1.13M | 23.96% |
| 2016-03-31 | $911.46K | -18.87% |
| 2015-12-31 | $1.12M | -14.56% |
| 2015-09-30 | $1.31M | 1.81% |
| 2015-06-30 | $1.29M | -27.77% |
| 2015-03-31 | $1.79M | 27.53% |
| 2014-12-31 | $1.40M | 7.72% |
| 2014-09-30 | $1.30M | 24.94% |
| 2014-06-30 | $1.04M | - |
| 2014-03-31 | $1.04M | 106.99% |
| 2013-12-31 | $503.23K | 100.00% |
| 2013-09-30 | - | 100.00% |
| 2013-06-30 | - | 100.00% |
| 2013-03-31 | - | 100.00% |
| 2012-12-31 | - | 100.00% |
| 2012-09-30 | - | 100.00% |
| 2012-06-30 | - | -100.00% |
| 2012-03-31 | $195.50K | - |
| 2011-12-31 | $195.50K | -75.95% |
| 2011-09-30 | $813.00K | 134.97% |
| 2011-06-30 | $346.00K | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | 100.00% |
| 2010-06-30 | - | 100.00% |
| 2010-03-31 | - | 100.00% |
| 2009-12-31 | - | 100.00% |
| 2009-09-30 | - | 100.00% |
| 2009-06-30 | - | 100.00% |
| 2009-03-31 | - | 100.00% |
| 2008-12-31 | - | 100.00% |
| 2008-09-30 | - | 100.00% |
| 2008-06-30 | - | 100.00% |
| 2008-03-31 | - | 100.00% |
| 2007-12-31 | - | - |
Capricor Therapeutics generated - in revenue during Q2 2025, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Capricor Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| VNDA | Vanda Pharmaceuticals | $198.77M | $52.59M |
| ALEC | Alector | $100.56M | $3.67M |
| SCPH | scPharmaceuticals | $36.33M | $11.75M |
| CAPR | Capricor Therapeutics | $22.27M | - |
| ACIU | AC Immune | $14.80M | - |
| IMMP | Immutep | $3.51M | $2.11M |
| CADL | Candel Therapeutics | - | - |
| ALDX | Aldeyra Therapeutics | - | - |
| KYTX | Kyverna Therapeutics | - | - |
| HUMA | Humacyte | - | $301.00K |
| MREO | Mereo BioPharma Group | - | - |